- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: DOJ Health Fraud Charges; Demand for Weight Loss Drugs; MDMA Therapy for PTSD
The Department of Justice (DOJ) charged almost 80 people in $2.5B health care fraud ruse; nearly 50% of US adults would spend $100/month on Wegovy, other weight loss medications; Australia is the first country to offer 3,4-methylenedioxymethamphetamine, commonly known as ecstasy or MDMA, for posttraumatic stress disorder (PTSD).
DOJ Files Charges in $2.5B Health Care Fraud Scheme
The Department of Justice (DOJ) has charged 78 people regarding their alleged connection in defrauding care programs for the elderly and people with disabilities of more than $2.5 billion, it declared Wednesday, according to The Hill. Included in the charges filed against them are allegations of telemedicine and pharmaceutical fraud, and opioid distribution claims. Most of the defendants acquired their money by making fraudulent Medicare requirement claims for things that were frequently ineligible.
Almost 50% of US Adults Would Shell Out $100/Month for Weight Loss Drugs
Nearly 50% of Americans would be prepared to spend up to $100 monthly for new weight loss drugs like Wegovy, which also marketed as Ozembic for diabetes, and 33% said they would open-endedly pay whatever they can manage to obtain the drugs, according to a survey by STAT and The Harris Poll, reported STAT. Even though 47% said they would be able to spend the money up to a specific point, like losing a fixed amount of weight or until a special event, demand is so high that almost 25% say that they would pay up to $250 monthly, and another 17% would be ready to pay as much as $500 monthly. The survey polled 2046 US adults and was administered in early June.
Australia First in the World to Offer MDMA for PTSD
Australia announced that it would become the first country in the world to permit psychiatrists to broadly prescribe 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), for the treatment of posttraumatic stress disorder (PTSD), according to The Washington Post. The unit of scientists at the University of Western Australia have been working to alter the chemical so that it’s better equipped to treat mental health conditions. The Therapeutic Goods Administration, Australia’s drug regulator, ruled that MDMA would be considered a controlled substance starting in July, and permit psilocybin, the active ingredient in magic mushrooms, to be used for treatment-resistant depression therapy.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
